
Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway
EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.